ModernGraham Valuation

Company Name:

Company Ticker PRGO Date of Analysis Perrigo Company plc Ordinary Shares



7/30/2016

Stage 1: Is this company suitable for the Defensive Investor or the Enterprising Investor?

Defensive Investor; must pass 6 out of the following 7 tests.

1.	. Adequate Size of the Enterprise	Market Cap > \$2Bil	\$13,044,717,400	Pass
2.	. Sufficiently Strong Financial Condition	Current Ratio > 2	1.42	Fail
3.	. Earnings Stability	Positive EPS for 10 years prior		Fail
4.	. Dividend Record	Dividend Payments for 10 years prior		Pass
5	. Earnings Growth	Increase of 33% in EPS in past 10 years using 3 year averages at beginning and end	98.66%	Pass
6.	. Moderate PEmg Ratio	PEmg < 20	44.74	Fail
7.	. Moderate Price to Assets	PB Ratio < 2.5 OR PB*PEmg < 50	1.33	Pass
Enterprising Investor; mi	ust pass 4 out of the following 5 tests, or be	suitable for the Defensive Investor.		
1.	. Sufficiently Strong Financial Condition	Current Ratio > 1.5	1.42	Fail
2.	. Sufficiently Strong Financial Condition	Debt to NCA < 1.1	6.67	Fail
3.	. Earnings Stability	Positive EPS for 5 years prior		Fail

Earnings Stability	Positive EPS for 5 years prior	Fail
4. Dividend Record	Currently Pays Dividend	Pass
5. Earnings Growth	EPSmg greater than 5 years ago	Fail

Suitability

Defensive	No
Enterprising	No

Stage 2: Determination of Intrinsic Value

	EPSmg		\$2.04
	MG Growth Estimate		-2.24%
	MG Value		\$8.21
	MG Value based on 3% Growth		\$29.62
	MG Value based on 0% Growth		\$17.36
	Market Implied Growth Rate		18.12%
MG Opinion			
	Current Price		\$91.39
	% of Intrinsic Value		1113.18%
	Opinion	Overvalued	
	MG Grade	F	

Stage 3: Information for Further Research

Net Current Asset Value (NCAV)	-\$48.22
Graham Number	\$0.00
PEmg	44.74
Current Ratio	1.42
PB Ratio	1.33
Current Dividend	\$0.52
Dividend Yield	0.57%
Number of Consecutive Years of Dividend Growth	13

Useful Links:

ModernGraham tagged articles Google Finance Yahoo Finance GuruFocus Morningstar MSN Money Seeking Alpha SEC Filings

EPS History		EPSmg History	
Next Fiscal Year Estimate	-\$0.53	Next Fiscal Year Estimate	\$2.0
Jun2014	\$1.77	Jun2014	\$3.3
Jun2013	\$4.68	Jun2013	\$3.8
Jun2012	\$4.27	Jun2012	\$3.1
Jun2011	\$3.63	Jun2011	\$2.4
Jun2010	\$2.40	Jun2010	\$1.6
Jun2009	\$1.54	Jun2009	\$0.8
Jun2008	\$1.43	Jun2008	\$0.3
Jun2007	\$0.79	Jun2007	-\$0.2
Jun2006	\$0.76	Jun2006	-\$0.6
Jun2005	-\$4.57	Jun2005	-\$0.9
Jun2004	\$1.11	Jun2004	\$0.7
Jun2003	\$0.76	Jun2003	\$0.5
Jun2002	\$0.67	Jun2002	\$0.3
Jun2001	\$0.37	Jun2001	\$0.1
Jun2000	\$0.26	Jun2000	\$0.0
Jun1999	\$0.02	Jun1999	\$0.0
Jun1998	-\$0.69	Balance Sheet Information	3/1/201
Jun1997	\$0.58	Total Current Assets	\$2,974,500,00
Jun1996	\$0.52	Total Current Liabilities	\$2,089,200,00
Jun1995	\$0.58	Long-Term Debt	\$5,902,700,00
		Total Assets	\$19,726,200,00
		Intangible Assets	\$15,552,100,00
		Total Liabilities	\$9,878,900,00
		Shares Outstanding (Diluted Average)	143,200,00





Disclaimer:

This valuation is not investment advice. Anyone who is considering making an investment decision should speak to a registered investment advisor. The author did not hold a position in any company mentioned in this article at the time of publication and had no intention of changing those holdings within the next 72 hours.

Recommended Reading:

Other	Perrigo Co PLC Valuation – January 2016 Update \$PRGO	
ModernGraham posts about the	Perrigo Company PLC Analysis – October 2015 Update \$PRGO	
company	Perrigo Company Analysis – July 2015 Update \$PRGO	
	24 Companies in the Spotlight This Week - 3/28/15	
	Perrigo Company plc Quarterly Valuation – March 2015 \$PRGO	
Other Madam Crack and	AbbVie Inc Valuation – July 2016 \$ABBV	
ModernGraham posts about related	Gilead Sciences Inc Valuation – July 2016 \$GILD	
companies	Eli Lilly and Company Valuation – July 2016 \$LLY	
	Zoetis Inc Valuation – June 2016 \$ZTS	
	Merck & Co Inc Valuation – March 2016 \$MRK	
	Bristol-Myers Squibb Company Valuation – February 2016 \$BMY	
	Amgen Inc Valuation – February 2016 \$AMGN	
	Merck & Co Inc Valuation – March 2016 \$MRK	

Bristol-Myers Squibb Company Valuation – February 2016 \$BMY

Amgen Inc Valuation – February 2016 \$AMGN